Treatment success rate for patients treated for MDR-TB in Belize
Belize: Treatment success rate for patients treated for MDR-TB was 100.0% in 2022. ▼ Falling
Latest (2022)
100.0%
Change on year
up 100.0%
World rank
1st
of 163 countries
All-time high
100.0%
in 2009
All-time low
50.0%
in 2013
Years of data
8
2009–2022
Treatment success rate for patients treated for MDR-TB in Belize, 2009–2022
Source: World Health Organization, Global Health Observatory.
Analysis
Belize recorded 100.0% for treatment success rate for patients treated for mdr-tb in 2022. That is the highest value across all 8 years on record.
That represents a change of up 100.0% on the previous year and up 100.0% over ten years.
Over the whole period, treatment success rate for patients treated for mdr-tb in Belize peaked at 100.0% in 2009 and was at its lowest, 50.0%, in 2013.
That places Belize 1st out of 163 countries with data for 2022, putting it in the top 10%.
Treatment success rate for patients treated for MDR-TB in Belize, year by year
| Year | Value | Change |
|---|---|---|
| 2009 | 100.0% | — |
| 2013 | 50.0% | -50.0% |
| 2014 | 100.0% | +100.0% |
| 2015 | 100.0% | +0.0% |
| 2018 | 100.0% | +0.0% |
| 2020 | 50.0% | -50.0% |
| 2021 | 50.0% | +0.0% |
| 2022 | 100.0% | +100.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 100.0% | 100.0% | 100.0% | 1 |
| 2010s | 87.5% | 50.0% | 100.0% | 4 |
| 2020s | 66.7% | 50.0% | 100.0% | 3 |
Countries ranked near Belize
- 1 New Zealand 100.0% compare
- 1 Sao Tome and Principe 100.0% compare
- 1 Jordan 100.0% compare
- 1 Serbia 100.0% compare
- 1 Kuwait 100.0% compare
- 1 Macau, China 100.0% compare
- 1 Mauritius 100.0% compare
- 1 Montenegro 100.0% compare
- 1 Bahamas 100.0% compare
- 1 Kiribati 100.0% compare
- 1 Cape Verde 100.0% compare
- 1 Puerto Rico 100.0% compare
- 1 Costa Rica 100.0% compare
- 1 Micronesia, Federated States of 100.0% compare
- 1 United Arab Emirates 100.0% compare
More health data for Belize
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.5114 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,415 deaths per 1,000 people (2090)
- Number of infants who die before age 1 9 deaths (2100)
- Population ages 65-69, male, annual growth rate 5.27 % change on previous year (2025)
- Population ages 65-69, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 65-69, male, per capita 0.0106 units per person (2025)
- Population ages 70-74, female, annual growth rate 5.66 % change on previous year (2025)
- Population ages 70-74, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 70-74, female, per capita 0.0075 units per person (2025)
Frequently asked questions
- What is treatment success rate for patients treated for mdr-tb in Belize?
- Treatment success rate for patients treated for mdr-tb in Belize was 100.0% in 2022, according to World Health Organization, Global Health Observatory.
- What is the highest treatment success rate for patients treated for mdr-tb recorded in Belize?
- The highest recorded value was 100.0% in 2009.
- What is the lowest treatment success rate for patients treated for mdr-tb recorded in Belize?
- The lowest recorded value was 50.0% in 2013.
- How does Belize rank for treatment success rate for patients treated for mdr-tb?
- Belize ranks 1st out of 163 countries with data for 2022.
- Is treatment success rate for patients treated for mdr-tb rising or falling in Belize?
- Over the last ten years it is up 100.0%. The long-run trend across the full record is falling.
- Where does this Belize data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Treatment success rate for patients treated for MDR-TB (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 8 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).